Forodesine in the treatment of cutaneous T-cell lymphoma.

about

Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma.

P2860

Q48248214-CE77040A-6109-4BA3-AA6B-1BFA7A6B373E

P2860

Forodesine in the treatment of cutaneous T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q39266443

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Forodesine in the treatment of cutaneous T-cell lymphoma.

@en

Forodesine in the treatment of cutaneous T-cell lymphoma.

@nl

type

Item

label

Forodesine in the treatment of cutaneous T-cell lymphoma.

@en

Forodesine in the treatment of cutaneous T-cell lymphoma.

@nl

prefLabel

Forodesine in the treatment of cutaneous T-cell lymphoma.

@en

Forodesine in the treatment of cutaneous T-cell lymphoma.

@nl

P1476

Forodesine in the treatment of cutaneous T-cell lymphoma.

@en

P2093

Daniel J Lewis

http://www.w3.org/2001/XMLSchema#string

Madeleine Duvic

http://www.w3.org/2001/XMLSchema#string

P2860

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment

Mycosis fungoides: pathophysiology and emerging therapies.

Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?

Cutaneous T-cell lymphoma: epidemiology, etiology, and classification.

Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?

P304

771-775

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1324569

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28447489

http://www.w3.org/2001/XMLSchema#string

Forodesine in the treatment of cutaneous T-cell lymphoma.

about

P2860

P2860

Forodesine in the treatment of cutaneous T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698